Every open market buy and sale of Mineralys Therapeutics, Inc. stock by its officers, directors and 10% owners over the last two years, straight from SEC Form 4 filings. Insiders are net sellers over the last 12 months: $8.8M bought and $71.3M sold.
Buying and selling by month
open market, last 12 monthsGet an alert when MLYS insiders trade
We read every Form 4 the moment the SEC posts it and tell you when an MLYS officer, director or 10% owner buys on the open market, or sells $250K or more outside a pre-arranged plan, by email or on your phone.
Insider alerts are part of AI Pro. Start with a free account, then add AI Pro when you want the alerts.
Every MLYS insider trade
2 years · newest first| Insider | Type | Price | Held after | Filed | |||
|---|---|---|---|---|---|---|---|
| Sep 30, 2026 | Jon CongletonCEO | Sale plan | 75,000 | $25.46 | $1.9M | 528,621 | Oct 2Form 4 |
| Sep 22, 2026 | Brian Taylor SlingsbyDirector | Sale | 104,320 | $28.81 | $3M | 7,805,718 | Sep 24Form 4 |
| Sep 21, 2026 | Eric WarrenChief Commercial Officer | Sale plan | 7,438 | $28.12 | $209K | 38,400 | Sep 22Form 4 |
| Sep 15, 2026 | Daphne KarydasDirector | Sale plan | 3,000 | $28.58 | $86K | 6,200 | Sep 17Form 4 |
| Aug 21, 2026 | Eric WarrenChief Commercial Officer | Sale plan | 7,437 | $25.98 | $193K | 38,400 | Aug 25Form 4 |
| Aug 10, 2026 | David Malcom RodmanChief Medical Officer | Sale plan | 2,170 | $27.09 | $59K | 51,384 | Aug 12Form 4 |
| Jul 21, 2026 | Eric WarrenChief Commercial Officer | Sale plan | 7,438 | $26.87 | $200K | 38,400 | Jul 23Form 4 |
| Jul 17, 2026 | David Malcom RodmanChief Medical Officer | Sale plan | 416 | $26.53 | $11K | 51,384 | Jul 20Form 4 |
| Jul 15, 2026 | David Malcom RodmanChief Medical Officer | Sale plan | 20,407 | $27.28 | $557K | 51,384 | Jul 15Form 4 |
| Jul 13, 2026 | Jon CongletonCEO | Sale plan | 10,700 | $27.24 | $291K | 603,621 | Jul 15Form 4 |
| Jul 9, 2026 | David Malcom RodmanChief Medical Officer | Sale plan | 2,171 | $30.30 | $66K | 57,733 | Jul 10Form 4 |
| Jun 30, 2026 | Jon CongletonCEO | Sale plan | 75,000 | $26.14 | $2M | 614,321 | Jun 30Form 4 |
| Jun 26, 2026 | Eric WarrenChief Commercial Officer | Sale plan | 104,124 | $25.90 | $2.7M | 38,400 | Jun 30Form 4 |
| Jun 17, 2026 | Daphne KarydasDirector | Sale plan | 3,000 | $25.00 | $75K | 6,200 | Jun 17Form 4 |
| Jun 17, 2026 | David Malcom RodmanChief Medical Officer | Sale plan | 14,474 | $24.19 | $350K | 57,095 | Jun 17Form 4 |
MLYS insider trading FAQ
Are MLYS insiders buying or selling?
Insiders are net sellers over the last 12 months. 1 insiders bought $8.8M of MLYS on the open market in 1 trades, and 7 sold $71.3M in 37 trades, 35% of that under pre-arranged trading plans.
When did an MLYS insider last buy shares?
Rajeev M. Shah (Director) bought 369,000 shares for $8.8M on Mar 30, 2026, reported on Mar 31, 2026.
When did an MLYS insider last sell shares?
Jon Congleton (CEO) sold 75,000 shares for $1.9M on Sep 30, 2026, under a pre-arranged trading plan.
What is a Form 4?
Company officers, directors and owners of more than 10% of the shares must report trades in the company's stock to the SEC on Form 4 within two business days. This page shows open market buys and sales only. Option exercises, stock awards, gifts and shares withheld for taxes are left out, since they are not decisions to buy or sell.
Why do insider sales matter less than buys?
Insiders sell for many reasons, such as taxes, diversification or a home purchase, and many sales are scheduled months ahead under a 10b5-1 trading plan. They buy on the open market mostly when they expect the shares to rise, which is why buying, and especially several insiders buying together, gets more attention.
For informational and educational purposes only. Not investment advice, and not a recommendation to buy or sell any security. Trades come from SEC Form 4 filings as reported by the insiders. Insiders have two business days to report, so a trade can be a few days old when it appears. See all insider cluster buys.
From SEC Form 4 filings · Not investment advice
